RLY-2608, RLY-2608
RLY-2608-201
Phase 2 small_molecule active
Quick answer
RLY-2608, RLY-2608 for PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation is a Phase 2 program (small_molecule) at Relay Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Relay Therapeutics
- Indication
- PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active